Insilico Medicine News and Activities

Insilico Medicine is a company listed under the stock ticker HKEX (US).

Acquisition, funding and merger involving Insilico Medicine.

• Insilico Medicine is now listed under ticker HKEX. (posted on January 20 2026).

View the org chart displaying its 22 main executives

Most searched biographies at Insilico Medicine

• Alex Zhavoronkov, Co-Chief Executive Officer and Chairman of the B...
• Denitsa Milanova, Director
• Long Shi, Director

Popular executive movements at Insilico Medicine

• Jue Wang has joined the company as Global Head of Business Development  (posted on June 19 2026).
• Halle Zhang has joined the company as Vice President, Clinical Development, Oncology  (posted on February 9 2026).
• Denitsa Milanova has joined the company as Director  (posted on February 9 2026).

Create your alert
to follow the executive moves at Insilico Medicine.

Insilico Medicine has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Insilico Medicine

• Pharma.AI Summer Update Preview: Drive the future of pharmaceutical intelligence
• Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
• Insilico Medicine Appoints Jue Wang, PhD as Global Head of Business Development
• Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science
• Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
• Advancing Drug Discovery from Automation to Autonomy: Insilico Medicine Announces LabClaw the Intelligent System
• Insilico Medicine and Saudi Aramco Introduce the “Sanity Pipeline” to Advance AI-driven Discovery of MOFs
• Insilico Medicine to Present Groundbreaking AI Retrosynthesis Research at ICML 2026: Introducing ChemCensor to Bring Real-World Chemistry Into AI Benchmarking
• Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women’s Health
• Insilico Medicine named to Fast Company’s annual list of the world’s most innovative companies of 2026
• View more press releases Close

Social media about Insilico Medicine

• Insilico Medicine on Wikipedia, Google News & Yahoo Finance
• Insilico Medicine on LinkedIn, X (Twitter) & YouTube